Envista Holdings Corp (NVST) Stock Analysis and Metrics

Envista Holdings

NYSE: NVST

$26.32 ▲ +0.15 (+0.57%)

At close: Jul 24, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap4.34 Bn

P/E64.11

P/S1.55

Div. Yield0.00

Total Debt (Qtr)1.44 Bn

Revenue Growth (1y) (Qtr)14.36

Add ratio to table…

About

Envista Holdings Corp is a global dental products company that offers a broad portfolio of more than 30 trusted brands, including Nobel Biocare, Ormco, DEXIS, and Kerr. The company designs, manufactures, and markets dental implants, orthodontic appliances, digital imaging systems, restorative materials, endodontic products, infection prevention solutions, and dental loupes. Its products serve the clinical needs of dental professionals for diagnosing, treating, and preventing oral conditions and for improving patient smiles. Envista Holdings Corp distributes its offerings to customers in over 130 countries through a large commercial organization and a network of distribution partners.

In 2025, Envista Holdings Corp generated total sales of $2.7 billion, of which approximately 85% were derived from sales of consumable products, services, and spare parts. The company's revenue comes from the sale of dental implant systems, orthodontic bracket systems and aligners, digital imaging equipment, restorative and endodontic materials, rotary burs, impression materials, bonding agents, cements, and infection prevention products. These products are sold to dental specialists, general dentists, dental hygienists, oral surgeons, dental laboratories, dental service organizations, and educational, medical, and governmental entities.

The company operates through the following segments: Specialty Products & Technologies and Equipment & Consumables.

• Specialty Products & Technologies: This segment develops, manufactures, and markets dental implant systems including regenerative solutions, dental prosthetics, and associated treatment software and technologies, as well as orthodontic bracket systems, aligners, lab products, and loupes. The segment markets these products primarily directly to end users through its commercial organization, with 84% of its 2025 sales being direct sales. In 2025, the segment generated $1,752.8 million in sales, representing a year over year sales increase of 8.4% and a core sales increase of 6.3%. Geographically, 41% of segment sales came from North America, 28% from Western Europe, 5% from other developed markets, and 26% from emerging markets. Sales of consumable products, services, and spare parts accounted for 93% of segment sales in 2025.

• Equipment & Consumables: This segment develops, manufactures, and markets dental equipment and supplies for dental offices, including digital imaging systems, software, and visualization and magnification systems, endodontic systems and related products, restorative materials and instruments, rotary burs, impression materials, bonding agents, and cements, and infection prevention products. In 2025, the segment generated $966.7 million in sales. Geographic breakdown shows 70% of segment sales from North America, 12% from Western Europe, 3% from other developed markets, and 15% from emerging markets. The segment distributes its products mainly through channel partners, which accounted for approximately 89% of its sales in 2025. Sales from consumable products, services, and spare parts made up approximately 70% of segment sales in 2025.

Envista Holdings Corp holds a leading position as one of the largest global dental products companies, with strong footholds in high growth segments such as dental implants, orthodontics, and digital imaging. The company benefits from a broad and deep product portfolio that spans premium and value brands, allowing it to meet diverse customer needs. Its competitive advantages include a legacy of innovation demonstrated by products such as NobelActive implants, Spark clear aligners, and DEXIS imaging systems, the proprietary Envista Business System that drives continuous improvement, strong brand recognition built over decades, a worldwide commercial footprint serving over 130 countries, and a significant presence in emerging markets that supplies a growing share of revenue. While the dental products industry is highly competitive, with rivals ranging from specialized niche players to large multinational corporations, Envista Holdings Corp differentiates itself through its integrated product offerings, commitment to innovation, and extensive customer education and support programs.

Envista Holdings Corp serves a diverse customer base that includes dental specialists such as orthodontists, periodontists, implantologists, and endodontists, as well as general dentists, dental hygienists, oral surgeons, dental laboratories, and dental service organizations. The company also sells to educational institutions, medical facilities, governmental agencies, and third party distributors. Among its customers, Henry Schein Inc represented approximately 12% of total sales in 2025, while no other single customer accounted for more than 10% of revenue in that year.

Investment Thesis

▲ Bull case

Envista is positioned to benefit from a structural shift toward digital dentistry and AI integration, where its DEXIS platform with DTX Studio Clinic leverages a massive installed base of 275,000 connected devices processing over 500 million images annually. This network creates a self-reinforcing flywheel: more data improves AI diagnostic accuracy, which drives higher adoption, generating even more data. Management underemphasized how this ecosystem could unlock recurring software revenue streams beyond hardware sales, especially as AI-driven treatment planning becomes standard of care. The large installed base provides a defensible moat that competitors cannot replicate quickly, turning diagnostics into a high-margin, sticky growth engine that could meaningfully uplift long-term margins beyond the current 14% adjusted EBITDA level.
The company’s pricing strategy, which aligns increases with procedure-level price changes rather than arbitrary hikes, remains underappreciated by the market as a sustainable lever for margin expansion. Despite macro volatility, Envista has maintained pricing discipline by avoiding overreach—evidenced by its ability to implement mid-year tariff-related increases without significant volume pushback, particularly in less price-sensitive categories like consumables and orthodontics. This approach allows Envista to capture value as dental providers’ revenues grow, creating a natural hedge against input cost inflation. With management noting they will reuse this framework if Middle East tensions fuel cost pressures, the strategy positions the company to grow EPS faster than revenue through operating leverage, especially as sales and marketing investments scale efficiently.
Envista’s capital allocation framework—prioritizing organic growth, then accretive M&A, then share buybacks—reveals a hidden catalyst in its $300 million incremental buyback authorization. While management framed this as returning surplus cash, the timing suggests confidence in sustained free cash flow generation exceeding 100% of adjusted net income, even after reinvesting in R&D and sales. The buyback size, equivalent to roughly one-third of annual free cash flow, implies management believes intrinsic value is significantly above current levels, particularly as the company laps difficult comps from China VBP headwinds in H2 2026. This disciplined approach, combined with a net debt-to-EBITDA ratio under 1x, provides flexibility to accelerate buybacks if FCF conversion outperforms guidance, creating a floor for EPS growth that the market is not pricing in.

Envista is positioned to benefit from a structural shift toward digital dentistry and AI integration, where its DEXIS platform with DTX Studio Clinic leverages a massive installed base of 275,000 connected devices processing over 500 million images annually. This network creates a self-reinforcing flywheel: more data improves AI diagnostic accuracy, which drives higher adoption, generating even more data. Management underemphasized how this ecosystem could unlock recurring software revenue streams beyond hardware sales, especially as AI-driven treatment planning becomes standard of care. The large installed base provides a defensible moat that competitors cannot replicate quickly, turning diagnostics into a high-margin, sticky growth engine that could meaningfully uplift long-term margins beyond the current 14% adjusted EBITDA level.
The company’s pricing strategy, which aligns increases with procedure-level price changes rather than arbitrary hikes, remains underappreciated by the market as a sustainable lever for margin expansion. Despite macro volatility, Envista has maintained pricing discipline by avoiding overreach—evidenced by its ability to implement mid-year tariff-related increases without significant volume pushback, particularly in less price-sensitive categories like consumables and orthodontics. This approach allows Envista to capture value as dental providers’ revenues grow, creating a natural hedge against input cost inflation. With management noting they will reuse this framework if Middle East tensions fuel cost pressures, the strategy positions the company to grow EPS faster than revenue through operating leverage, especially as sales and marketing investments scale efficiently.
Envista’s capital allocation framework—prioritizing organic growth, then accretive M&A, then share buybacks—reveals a hidden catalyst in its $300 million incremental buyback authorization. While management framed this as returning surplus cash, the timing suggests confidence in sustained free cash flow generation exceeding 100% of adjusted net income, even after reinvesting in R&D and sales. The buyback size, equivalent to roughly one-third of annual free cash flow, implies management believes intrinsic value is significantly above current levels, particularly as the company laps difficult comps from China VBP headwinds in H2 2026. This disciplined approach, combined with a net debt-to-EBITDA ratio under 1x, provides flexibility to accelerate buybacks if FCF conversion outperforms guidance, creating a floor for EPS growth that the market is not pricing in.

▼ Bear case

Envista’s exposure to China’s Volume-Based Procurement (VBP) program remains a material and underdiscussed risk, with Q1 showing double-digit declines in implant sales there despite management framing it as temporary channel destocking. The VBP process for implants and orthodontics is expected to begin in Q2 or Q3 2026, but the company lacks visibility into final pricing terms, and its reliance on channel partners to manage inventory could prolong the downturn. Unlike past cycles, VBP now includes bundled bidding and stricter volume commitments, which could force deeper, longer-lasting price cuts. Management’s assumption that strong global brands will benefit from increased patient volume overlooks the likelihood that VBP will accelerate consolidation toward lower-cost domestic competitors, eroding Envista’s premium pricing power in the world’s fastest-growing dental market.
The company’s dependence on incremental billing days and product deferrals to flatter growth metrics creates a misleading perception of underlying momentum. Q1’s 9.5% core growth included a 4.5% tailwind from four extra billing days and a $9 million benefit from Spark deferrals, leaving normalized growth at just ~4%—at the low end of its 2%–4% full-year guidance range. This suggests organic growth is stagnating despite double-digit sales and marketing and R&D investments, raising concerns about diminishing returns on innovation spend. With management acknowledging that pricing will revert to “normal range ex China” after lapsing tariff increases, the tailwinds flattering 2025 performance are set to reverse, leaving Q3 and Q4 2026 vulnerable to deceleration that could breach guidance if macro headwinds intensify.
Envista’s elevated investment in sales, marketing, and R&D—up double digits in Q1—may not be translating into durable competitive advantages, particularly in commoditized segments like consumables and diagnostics. While the company cites share gains in Metrex antimicrobials and DEXIS imaging, these businesses face intensifying private-label competition and downward pricing pressure from group purchasing organizations. The diagnostics segment, despite DEXIS’s installed base, is seeing AI tools become table stakes, with rivals rapidly closing the gap in software capabilities. Management’s focus on “clinical education and customer support” as growth drivers lacks measurable metrics, and the lack of discussion on customer retention or churn rates in Q&A suggests potential weakness in stickiness. Without clear evidence that innovation is creating pricing power or reducing customer acquisition costs, these investments risk becoming a margin drag rather than a growth catalyst.

Envista’s exposure to China’s Volume-Based Procurement (VBP) program remains a material and underdiscussed risk, with Q1 showing double-digit declines in implant sales there despite management framing it as temporary channel destocking. The VBP process for implants and orthodontics is expected to begin in Q2 or Q3 2026, but the company lacks visibility into final pricing terms, and its reliance on channel partners to manage inventory could prolong the downturn. Unlike past cycles, VBP now includes bundled bidding and stricter volume commitments, which could force deeper, longer-lasting price cuts. Management’s assumption that strong global brands will benefit from increased patient volume overlooks the likelihood that VBP will accelerate consolidation toward lower-cost domestic competitors, eroding Envista’s premium pricing power in the world’s fastest-growing dental market.
The company’s dependence on incremental billing days and product deferrals to flatter growth metrics creates a misleading perception of underlying momentum. Q1’s 9.5% core growth included a 4.5% tailwind from four extra billing days and a $9 million benefit from Spark deferrals, leaving normalized growth at just ~4%—at the low end of its 2%–4% full-year guidance range. This suggests organic growth is stagnating despite double-digit sales and marketing and R&D investments, raising concerns about diminishing returns on innovation spend. With management acknowledging that pricing will revert to “normal range ex China” after lapsing tariff increases, the tailwinds flattering 2025 performance are set to reverse, leaving Q3 and Q4 2026 vulnerable to deceleration that could breach guidance if macro headwinds intensify.
Envista’s elevated investment in sales, marketing, and R&D—up double digits in Q1—may not be translating into durable competitive advantages, particularly in commoditized segments like consumables and diagnostics. While the company cites share gains in Metrex antimicrobials and DEXIS imaging, these businesses face intensifying private-label competition and downward pricing pressure from group purchasing organizations. The diagnostics segment, despite DEXIS’s installed base, is seeing AI tools become table stakes, with rivals rapidly closing the gap in software capabilities. Management’s focus on “clinical education and customer support” as growth drivers lacks measurable metrics, and the lack of discussion on customer retention or churn rates in Q&A suggests potential weakness in stickiness. Without clear evidence that innovation is creating pricing power or reducing customer acquisition costs, these investments risk becoming a margin drag rather than a growth catalyst.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Instruments & Supplies

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	ALC	Alcon Inc	33,163,703.85 Bn	498,335.12	3.14 Mn	4.16 Bn
2	ISRG	Intuitive Surgical Inc	119.67 Bn	37.90	0.00 Mn	-
3	BDX	Becton Dickinson & Co	43.92 Bn	37.38	0.00 Mn	17.28 Bn
4	MDLN	Medline Inc.	31.71 Bn	56.52	0.00 Mn	12.57 Bn
5	RMD	Resmed Inc	28.46 Bn	18.73	0.00 Mn	0.66 Bn
6	WST	West Pharmaceutical Services Inc	23.80 Bn	45.05	0.00 Mn	0.20 Bn
7	COO	Cooper Companies, Inc.	13.77 Bn	58.38	0.00 Mn	2.46 Bn
8	SOLV	Solventum Corp	13.63 Bn	9.51	0.00 Mn	5.08 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password